Protara Therapeutics’ TARA-002: Promising Phase 2 Results and Market Potential in NMIBC Treatment

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Protara Therapeutics (TARA – Research Report). The associated price target is $23.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors surrounding Protara Therapeutics’ TARA-002. The updated interim data from the Phase 2 ADVANCED-2 trial presented at AUA 2025 highlighted TARA-002’s potential as a best-in-class treatment for high-grade non–muscle invasive bladder cancer (NMIBC). The trial results demonstrated a notable efficacy signal, especially in BCG-unresponsive patients, with a complete response rate of 100% at any time and significant durability observed at 12 months.
Furthermore, discussions with Protara’s management reinforced the promising outlook for TARA-002 in the intravesical immunotherapy space. The management team emphasized the therapy’s potential to fill existing gaps left by other treatments like cretostimogene and TAR-200, which have lower complete response rates. They also highlighted the substantial unmet need in the market, suggesting that TARA-002 could establish a strong presence. The ongoing maturation of the data, particularly regarding long-term durability, is expected to further enhance the therapy’s commercial viability.

In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $22.00 price target.